Two Sigma Investments’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-14,620
| Closed | -$329K | – | 3210 |
|
|
2024
Q4 | $329K | Sell |
14,620
-7,460
| -34% | -$168K | ﹤0.01% | 2645 |
|
|
2024
Q3 | $564K | Buy |
22,080
+4,843
| +28% | +$124K | ﹤0.01% | 2352 |
|
|
2024
Q2 | $403K | Buy |
+17,237
| New | +$403K | ﹤0.01% | 2389 |
|
|
2022
Q3 | – | Sell |
-29,784
| Closed | -$145K | – | 2508 |
|
|
2022
Q2 | $145K | Sell |
29,784
-31,252
| -51% | -$152K | ﹤0.01% | 2153 |
|
|
2022
Q1 | $459K | Sell |
61,036
-4,515
| -7% | -$34K | ﹤0.01% | 2022 |
|
|
2021
Q4 | $590K | Buy |
65,551
+3,177
| +5% | +$28.6K | ﹤0.01% | 1911 |
|
|
2021
Q3 | $1.02M | Buy |
+62,374
| New | +$1.02M | ﹤0.01% | 1678 |
|
|
2021
Q2 | – | Sell |
-12,732
| Closed | -$430K | – | 2529 |
|
|
2021
Q1 | $430K | Buy |
+12,732
| New | +$430K | ﹤0.01% | 1926 |
|